Prognostic significance of serum inflammation indices for different tumor infiltrative pattern types of gastric cancer

Figure 4 Survival curve analyses based on postoperative chemotherapy. A-C: Survival curves with and without postoperative chemotherapy in all the expansive growth type (INFa) gastric cancer (GC) patients, INFa GC patients with systemic immune-inflammation index (SII) ≤ 523.01, and INFa GC patients with SII > 523.01; D-F: Survival curves with and without postoperative chemotherapy in all the intermediate type (INFb), GC patients, INFb GC patients with platelet-lymphocyte ratio (PLR) ≤ 134.02, and INFb GC patients with PLR > 134.02; G–I: Survival curves with and without postoperative chemotherapy in all the infiltrative growth type (INFc) GC patients, INFc GC patients with PLR ≤ 134.02, and INFc GC patients with PLR > 134.02. INFa: The expansive growth type; INFb: The intermediate type; INFc: The infiltrative growth type; PLR: Platelet-lymphocyte ratio; SII: Systemic immune-inflammation index.